ICH E2B(R3) deadline set

Drug companies are being told to rebuild one of the least visible parts of medicine by October 1, 2026: the electronic form used to tell regulators that one specific patient had one specific bad reaction. The Food and Drug Administration said those postmarketing case reports must switch to the International Council for Harmonisation’s E2B(R3) format for drugs, biologics, and drug- or biologic-led combination products sent through its next-generation gateway. (federalregister.gov) An individual case safety report is the pharmacovigilance equivalent of an incident report after a plane problem: one patient, one product, one event, plus dates, doses, test results, and outcomes. The International Council for Harmonisation built E2B so those reports can move between companies and regulators without being retyped by hand. (ich.org) The old version was called E2B(R2), and it dates back to work released in 2000 and 2001. E2B(R3) grew out of a later rewrite that the International Council for Harmonisation developed with standards bodies including International Organization for Standardization and Health Level Seven so the same safety message could work across more systems. (ich.org) This is not a new safety rule telling companies what to report. It is a plumbing rule telling them how the report has to be structured when it reaches the Food and Drug Administration Adverse Event Monitoring System, which the agency now calls the Adverse Event Monitoring System and notes was formerly the Food and Drug Administration Adverse Event Reporting System. (federalregister.gov, fda.gov) The format matters because safety databases are only as useful as the fields inside them. E2B(R3) is built around a more detailed message model, and the International Council for Harmonisation says it constrains a broader International Organization for Standardization and Health Level Seven standard so regions can exchange the same core case with local additions. (ich.org) The Food and Drug Administration has already spent two years laying the tracks. It published a regional implementation guide in 2024 for drug and biological products, plus data-element spreadsheets, business rules, sample Extensible Markup Language files, and technical conformance documents so companies could test their systems before the hard deadline arrived. (fda.gov, fda.gov) Europe is part of the reason this change has been hanging over the industry for years. The European Medicines Agency lists the E2B(R3) scientific guideline as legally effective from July 1, 2013, so multinational drugmakers have long had to think about how to send one safety case into more than one regulator’s system. (ema.europa.eu) That leaves companies with a practical job, not a legal theory seminar. Every vendor connection, validation rule, acknowledgment message, attachment workflow, and case-processing screen that still assumes the older format has to work in E2B(R3) before October 1, 2026, or the report may fail at the electronic door. (fda.gov, federalregister.gov) The quiet part of this story is that regulators are trying to make a side effect in Ohio look like the same digital object as a side effect in Paris or Tokyo. When the fields line up, software can sort, merge, and analyze signals faster, and that is the whole point of forcing thousands of safety reports into one shared grammar. (ich.org, ema.europa.eu, federalregister.gov)